Targeting the release of drugs in specific sites of the upper GI tract would meet local therapeutic goals, improve the bioavailability of specific drugs and help overcoming compliance-related limitations, especially in chronic illnesses of great social/economic impact and involving polytherapies (e.g. Parkinson's and Alzeimer's disease, tubercolosis, malaria, HIV, HCV). It has been traditionally pursued using gastroretentive (GR) systems, i.e. low-density, high-density, magnetic, adhesive and expandable devices. More recently, the interest towards oral administration of biologics has prompted the development of novel drug delivery systems (DDSs) provided with needles and able to inject different formulations in the mucosa of the upper GI tract and particularly of esophagus, stomach or small intestine. Besides comprehensive literature analysis, DDSs identified as smart devices in view of their high degree of complexity in terms of design, working mechanism, materials employed and manufacturing steps were discussed making use of graphic tools.

Administration strategies and smart devices for drug release in specific sites of the upper GI tract / M. Uboldi, A. Melocchi, S. Moutaharrik, L. Palugan, M. Cerea, A. Foppoli, A. Maroni, A. Gazzaniga, L. Zema. - In: JOURNAL OF CONTROLLED RELEASE. - ISSN 1873-4995. - 348:(2022 Aug), pp. 537-552. [10.1016/j.jconrel.2022.06.005]

Administration strategies and smart devices for drug release in specific sites of the upper GI tract

M. Uboldi
Primo
;
A. Melocchi
Secondo
;
S. Moutaharrik;L. Palugan;M. Cerea;A. Foppoli;A. Maroni;A. Gazzaniga
Penultimo
;
L. Zema
Ultimo
2022-08

Abstract

Targeting the release of drugs in specific sites of the upper GI tract would meet local therapeutic goals, improve the bioavailability of specific drugs and help overcoming compliance-related limitations, especially in chronic illnesses of great social/economic impact and involving polytherapies (e.g. Parkinson's and Alzeimer's disease, tubercolosis, malaria, HIV, HCV). It has been traditionally pursued using gastroretentive (GR) systems, i.e. low-density, high-density, magnetic, adhesive and expandable devices. More recently, the interest towards oral administration of biologics has prompted the development of novel drug delivery systems (DDSs) provided with needles and able to inject different formulations in the mucosa of the upper GI tract and particularly of esophagus, stomach or small intestine. Besides comprehensive literature analysis, DDSs identified as smart devices in view of their high degree of complexity in terms of design, working mechanism, materials employed and manufacturing steps were discussed making use of graphic tools.
4D printing; Expandable drug delivery systems; Oral biologics; Piercing drug delivery systems; Retentive drug delivery systems; Submucosal injection;
Settore CHIM/09 - Farmaceutico Tecnologico Applicativo
17-giu-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
Pre-print.pdf

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 6.11 MB
Formato Adobe PDF
6.11 MB Adobe PDF Visualizza/Apri
1-s2.0-S0168365922003339-main_compressed.pdf

solo utenti autorizzati

Tipologia: Publisher's version/PDF
Dimensione 1.04 MB
Formato Adobe PDF
1.04 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/932323
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact